ValuEngine downgraded shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) from a hold rating to a sell rating in a research note published on Friday.

Other equities analysts also recently issued reports about the company. JMP Securities downgraded Syros Pharmaceuticals from an outperform rating to a market perform rating in a research report on Thursday, August 10th. Wedbush reaffirmed an outperform rating and issued a $22.84 price target (down from $25.00) on shares of Syros Pharmaceuticals in a report on Thursday, August 10th. Zacks Investment Research downgraded Syros Pharmaceuticals from a buy rating to a hold rating in a report on Wednesday, July 19th. Cowen and Company reaffirmed a buy rating on shares of Syros Pharmaceuticals in a report on Wednesday, August 9th. Finally, Oppenheimer Holdings, Inc. set a $28.00 price target on Syros Pharmaceuticals and gave the company a buy rating in a report on Monday, June 12th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of $22.97.

Syros Pharmaceuticals (NASDAQ SYRS) opened at 14.93 on Friday. Syros Pharmaceuticals has a 12 month low of $10.22 and a 12 month high of $17.89. The stock’s market capitalization is $392.06 million. The company has a 50 day moving average of $16.38 and a 200 day moving average of $16.38.

Syros Pharmaceuticals (NASDAQ:SYRS) last announced its quarterly earnings data on Wednesday, August 9th. The company reported ($0.52) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.55) by $0.03. On average, equities analysts predict that Syros Pharmaceuticals will post ($2.09) EPS for the current year.

TRADEMARK VIOLATION WARNING: “Syros Pharmaceuticals, Inc. (SYRS) Downgraded by ValuEngine” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.dailypolitical.com/2017/09/25/syros-pharmaceuticals-inc-syrs-downgraded-by-valuengine.html.

In related news, insider Eric R. Olson sold 12,500 shares of the company’s stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $21.85, for a total value of $273,125.00. Following the completion of the transaction, the insider now directly owns 12,500 shares of the company’s stock, valued at $273,125. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Richard A. Young sold 3,282 shares of the company’s stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $22.00, for a total value of $72,204.00. Following the completion of the transaction, the director now directly owns 420,101 shares of the company’s stock, valued at $9,242,222. The disclosure for this sale can be found here. Insiders sold 21,564 shares of company stock valued at $476,803 over the last ninety days.

A number of institutional investors and hedge funds have recently made changes to their positions in SYRS. Wells Fargo & Company MN acquired a new position in Syros Pharmaceuticals in the first quarter valued at approximately $225,000. Bank of New York Mellon Corp acquired a new stake in shares of Syros Pharmaceuticals in the first quarter valued at approximately $185,000. Redmile Group LLC boosted its holdings in shares of Syros Pharmaceuticals by 0.5% in the first quarter. Redmile Group LLC now owns 952,740 shares of the company’s stock valued at $15,177,000 after acquiring an additional 4,300 shares during the period. Schwab Charles Investment Management Inc. acquired a new stake in shares of Syros Pharmaceuticals in the second quarter valued at approximately $343,000. Finally, Rhumbline Advisers acquired a new stake in shares of Syros Pharmaceuticals in the second quarter valued at approximately $198,000. 59.61% of the stock is owned by hedge funds and other institutional investors.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.